Flow Chemistry Company Moves Ahead
News Jan 14, 2008
Significant developments are reported by Uniqsis, the Cambridge-based joint venture company formed in January 2007 to develop a new concept in flow chemistry, leading to the launch of the FlowSyn™ Continuous Flow Reactor at the end of last year. FlowSyn fully integrates all the essential elements for flow chemistry into a single, user-friendly package, and was developed from concept to finished product in less than a year. The first systems are already in use in pharmaceutical development laboratories.
Uniqsis Managing Director Martyn Fordham said “It’s been an incredibly busy but rewarding year. The development team took FlowSyn from concept design and first prototype phases through to beta trial systems for pilot customers and now to the manufacture of fully standards-tested production models, and all in less than 12 months.”
The FlowSyn technical team has also been given a real boost by the arrival of Dr Mark Ladlow, a leading authority on flow chemistry. Mark was until recently head of the GSK Cambridge Technology Laboratory based within the University of Cambridge, where in recent years he has collaborated closely with Professor Steven Ley on developing flow chemistry as an emerging new chemistry technology. Following a period as an independent consultant developing flow chemistry applications, he has now joined Uniqsis as Chief Scientific Officer.
World-wide availability of FlowSyn is also expanding, with new distributors appointed in France, USA (Uniqsis will be exhibiting at Pittcon 2008), Italy and India.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE